To confirm this hypothesis, we seeded both of the tumor ovarian cell lines to form tumorspheres and treated them with suboptimal doses of cisplatin (IC30; 0.3 μM) or carboplatin (IC30; 0.3 μM) (Fig. 5 and Additional file 1: Figure S7) alone or in combination with suboptimal doses of inhibitors of the stem cell-related genes from our profile (Additional file 1: Table S4), such as DAPT (5 μM), a NOTCH inhibitor whose target is γ-secretase, imatinib (8 μM), a C-KIT inhibitor, PD98059 (15 μM), a MAPK inhibitor, and BEZ235 (10 μM), a PI3K inhibitor. Here, PIK3CA is linked to neoplasm.